Back to News
Market Impact: 0.2
Lundbeck presents Phase Ib data for Lu AF28996 in advanced Parkinson's disease, as Phase II trial begins
Source: PR Newswire
Healthcare & Biotech
An 18-week, open-label Phase Ib trial of investigational Lu AF28996 in people with advanced Parkinson’s disease provided initial safety and tolerability data. Most treatment-emergent adverse events were reported as mild; the article excerpt provides no efficacy results or further safety figures.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.15
More News
- Why is Telix Pharmaceuticals stock rallying today?
- Why is Natera stock sliding today?
- ArriVent BioPharma Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into ArriVent BioPharma (AVBP)
- Xenon Pharmaceuticals stock hits 52-week low at 36.06 USD
- LQDA SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving Liquidia Corporation
- Why is Illumina stock sliding today?